In vitro antifungal activity of hydroxychavicol isolated from Piper betle L.
BACKGROUND
Hydroxychavicol, isolated from the chloroform extraction of the aqueous leaf extract of Piper betle L., (Piperaceae) was investigated for its antifungal activity against 124 strains of selected fungi. The leaves of this plant have been long in use tropical countries for the preparation of traditional herbal remedies.


METHODS
The minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of hydroxychavicol were determined by using broth microdilution method following CLSI guidelines. Time kill curve studies, post-antifungal effects and mutation prevention concentrations were determined against Candida species and Aspergillus species "respectively". Hydroxychavicol was also tested for its potential to inhibit and reduce the formation of Candida albicans biofilms. The membrane permeability was measured by the uptake of propidium iodide.


RESULTS
Hydroxychavicol exhibited inhibitory effect on fungal species of clinical significance, with the MICs ranging from 15.62 to 500 microg/ml for yeasts, 125 to 500 microg/ml for Aspergillus species, and 7.81 to 62.5 microg/ml for dermatophytes where as the MFCs were found to be similar or two fold greater than the MICs. There was concentration-dependent killing of Candida albicans and Candida glabrata up to 8 x MIC. Hydroxychavicol also exhibited an extended post antifungal effect of 6.25 to 8.70 h at 4 x MIC for Candida species and suppressed the emergence of mutants of the fungal species tested at 2 x to 8 x MIC concentration. Furthermore, it also inhibited the growth of biofilm generated by C. albicans and reduced the preformed biofilms. There was increased uptake of propidium iodide by C. albicans cells when exposed to hydroxychavicol thus indicating that the membrane disruption could be the probable mode of action of hydroxychavicol.


CONCLUSIONS
The antifungal activity exhibited by this compound warrants its use as an antifungal agent particularly for treating topical infections, as well as gargle mouthwash against oral Candida infections.
Ali
Intzar
I
Clinical Microbiology Division Indian Institute of Integrative Medicine, Canal Road, Jammu-180 001, India.
Khan
Farrah G
FG
Suri
Krishan A
KA
Gupta
Bishan D
BD
Satti
Naresh K
NK
Dutt
Prabhu
P
Afrin
Farhat
F
Qazi
Ghulam N
GN
Khan
Inshad A
IA
D000935:Antifungal Agents / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects; D018441:Biofilms / Q000187:drug effects / Q000254:growth & development; D002175:Candida / Q000187:drug effects / Q000502:physiology; D005054:Eugenol / Q000031:analogs & derivatives* / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D005658:Fungi / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000187:drug effects; D031721:Piper betle / Q000737:chemistry*; D018515:Plant Leaves / Q000737:chemistry
D000935:Antifungal Agents; C051268:2-hydroxychavicol; D005054:Eugenol